MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (” MyMD” or “the Company”), a professional phase pharmaceutical firm devoted to extending healthy and balanced lifespan, today revealed that the very first patient has actually been enlisted in the Company’s Phase 2 professional test of lead candidate MYMD-1, a dental immune regulator medicine, as a therapy for postponing aging and also increasing healthy and balanced life-span.
The main endpoint for the Phase 2 double-blind, placebo-controlled medical trial is to attain a decrease in the distributing degrees of (TNF-α), tumor necrosis factor receptor I (TNFRI) as well as IL-6. TNF-α and also IL-6 are the healthy proteins in the body that create inflammation as well as help trigger the procedure of aging. The secondary actions of the trial will certainly be the security, tolerability, as well as pharmacokinetics in this populace of individuals.
” In a Phase 1 scientific trial of MYMD-1, we showed the medication’s statistically significant efficiency in minimizing levels of TNF-α, a principal in creating pathological aging, in the blood. The FDA has authorized TNF-α decrease as the key endpoint for our Stage 2 research study, which our company believe placements us well for a successful Phase 2 end result,” claimed Chris Chapman, M.D., President, Supervisor and also Principal Medical Officer of MyMD. “The initiation of client enrollment in this research study breakthroughs our objective to slow down the aging process, prevent loss of muscle mass cells in aging, limit frailty, and prolong healthy and balanced lifespan.”
MyMD has mentioned that there are no FDA-approved medications for treating aging problems as well as prolonging healthy and balanced life-span people, a market expected to be at least $600 billion by 20251 according to a major investment bank. TNF-α blockers are one of the most proposed medicines by earnings, a global market of around $40 billion each year,2 and also, according to Nature Aging journal,3 a stagnation in aging that would increase life span by one year deserves $38 trillion and by 10 years is worth $367 trillion.
In addition to aging, MYMD-1’s distinct action in controling the immune system and also treating chronic inflammation is being established for the treatment of autoimmune disease, including rheumatoid arthritis (RA), several sclerosis (MS), diabetes, and also inflammatory bowel illness.
” We intend to begin composing methods for a Phase 2 pilot study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The climbing prevalence of rheumatoid arthritis and also other autoimmune and inflammatory conditions are driving need for TNF inhibitors like MYMD-1, and also we believe our orally administered medication with extremely reduced toxicity would certainly be turbulent to the $60 billion market for RA if authorized by the FDA for this sign.”
Rheumatoid arthritis influences approximately 40 million people globally.4.
Originally established for autoimmune illness, MYMD-1’s main objective is to slow the aging process, avoid sarcopenia as well as frailty, as well as prolong healthy lifespan. Because it can cross the blood-brain barrier and also access to the central nerves (CNS), MYMD-1 is additionally placed to be a possible treatment for brain-related disorders. Its device of activity as well as efficiency in diseases consisting of several sclerosis (MS) and also thyroiditis have been researched via collaborations with several academic organizations. MYMD-1 is additionally showing pledge in pre-clinical studies as a prospective treatment for post- COVID-19 difficulties and also as an anti-fibrotic and also anti-proliferation therapeutic.
MYMD-1 has revealed efficiency in pre-clinical research studies in controling the body immune system by doing as a selective inhibitor of lump death factor-alpha (TNF-α), a vehicle driver of chronic swelling. Unlike various other treatments, MYMD-1 has been received these pre-clinical research studies to selectively obstruct TNF-α when it comes to be overactivated in autoimmune diseases and also cytokine storms, but not obstruct it from doing its typical task of being an initial -responder to any kind of routine kind of modest infection. MYMD-1’s simplicity of oral application is one more differentiator compared to presently readily available TNF-α blockers, all of which call for distribution by injection or infusion. No approved TNF prevention has actually ever been dosed orally. Additionally, the medication is not immunosuppressive and has actually not been shown to create the serious adverse effects typical with typical treatments that treat inflammation.
Concerning MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a scientific stage pharmaceutical business devoted to extending healthy and balanced life expectancy, is concentrated on establishing two unique restorative platforms that deal with the sources of illness rather than only addressing the signs. MYMD-1 is a drug platform based upon a scientific stage tiny particle that regulates the body immune system to manage TNF-α, which drives chronic swelling, and various other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to postpone aging, rise longevity, and also deal with autoimmune illness and COVID-19- connected clinical depression. The Business’s second medicine system, Supera-CBD, is being created to deal with persistent discomfort, dependency as well as epilepsy. Supera-CBD is an unique synthetic by-product of cannabidiol (CBD) and is being established to resolve and surpass the rapidly growing CBD market, which includes both FDA authorized medicines and CBD items not presently regulated as medications. For more information, go to www.mymd.com.